Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients With Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as Intermediate or High Risk by a 14-Gene Prognostic Assay

NCT01817192 is registered in ClinicalTrials.gov with Razor Genomics as lead sponsor.

NCT NCT01817192
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01817192 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients With Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as Intermediate or High Risk by a 14-Gene Prognostic Assay
Lead sponsor
Razor Genomics
Phase
Not applicable
Overall status
Active, not recruiting
Start date
September 11, 2020
Completion date
May 15, 2027
Enrollment
420 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer